{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:44:15Z","timestamp":1758807855378},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T00:00:00Z","timestamp":1477526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011068","name":"Fondation Saint-Luc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011068","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Fonds Pierre et Colette Bauchau"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0165631","type":"journal-article","created":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T17:36:05Z","timestamp":1477589765000},"page":"e0165631","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism"],"prefix":"10.1371","volume":"11","author":[{"given":"Le\u00efla","family":"Belkhir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Elens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Zech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadtha","family":"Panin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Cyr","family":"Yombi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Vandercam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Haufroid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,10,27]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40265-013-0159-3","article-title":"Darunavir: a review of its use in the management of HIV-1 infection","volume":"74","author":"ED Deeks","year":"2014","journal-title":"Drugs"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00003495-200969040-00007","article-title":"Darunavir: a review of its use in the management of HIV infection in adults","volume":"69","author":"K McKeage","year":"2009","journal-title":"Drugs"},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/QAD.0b013e328013d9d7","article-title":"Efficacy and safety of TMC114\/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1","volume":"21","author":"C Katlama","year":"2007","journal-title":"Aids"},{"issue":"9","key":"ref4","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2165\/00003088-200746090-00002","article-title":"Clinical pharmacokinetics of darunavir","volume":"46","author":"M Rittweger","year":"2007","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"ref5","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1128\/AAC.49.6.2314-2321.2005","article-title":"TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates","volume":"49","author":"S De Meyer","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"ref6","unstructured":"Prezista\u2122 (darunavir), prescribing information. Janssen Pharmaceuticals, Inc. 2006 revised in May 2015. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.prezista.com\/sites\/default\/files\/pdf\/us_package_insert.pdf\" xlink:type=\"simple\">https:\/\/www.prezista.com\/sites\/default\/files\/pdf\/us_package_insert.pdf<\/ext-link>."},{"issue":"9568","key":"ref7","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","article-title":"Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials","volume":"369","author":"B Clotet","year":"2007","journal-title":"Lancet"},{"issue":"13","key":"ref8","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e32832d7350","article-title":"Once-daily darunavir\/ritonavir vs. lopinavir\/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis","volume":"23","author":"AM Mills","year":"2009","journal-title":"Aids"},{"key":"ref9","unstructured":"Sekar V. S-GS, Lefebvre E., Hoetelmans R. Clinical pharmacology of TMC114 \u2013a potent HIV protease inhibitor. AIDS 2006\u2014XVI International AIDS Conference: Abstract no TUPE0083. 2006."},{"key":"ref10","unstructured":"Hoetelmans R VdSI, De Pauw M, et al. TMC114, a next generation HIV protease inhibitor: pharmacokinetics and safety following oral administration of multiple doses with and without low doses of ritonavir in healthy volunteers. 10th Conference on Retroviruses and Opportunistic Infections; February 10\u201314, 2003;Boston. Abstract 549."},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.clinthera.2009.04.020","article-title":"Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV","volume":"31","author":"DS Schiller","year":"2009","journal-title":"Clin Ther"},{"issue":"12","key":"ref12","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1128\/AAC.48.12.4680-4686.2004","article-title":"TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1","volume":"48","author":"K Andries","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"9581","key":"ref13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)61047-2","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial","volume":"370","author":"JV Madruga","year":"2007","journal-title":"Lancet"},{"issue":"9581","key":"ref14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(07)61048-4","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial","volume":"370","author":"A Lazzarin","year":"2007","journal-title":"Lancet"},{"key":"ref15","unstructured":"Intelence\u2122 (etravirine) tablets: full prescribing information. Janssen Pharmaceuticals, Inc. 2008 Revised August 2014. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.intelence.com\/shared\/product\/intelence\/prescribing-information.pdf\" xlink:type=\"simple\">http:\/\/www.intelence.com\/shared\/product\/intelence\/prescribing-information.pdf<\/ext-link>."},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/jcph.214","article-title":"The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects","volume":"54","author":"TN Kakuda","year":"2014","journal-title":"Journal of clinical pharmacology"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1124\/dmd.111.044404","article-title":"Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism","volume":"40","author":"LJ Yanakakis","year":"2012","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"},{"key":"ref18","unstructured":"European Medicines Agency. Intelence tablets: summary of product characteristics (online). Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000900\/WC500034180.pdf\" xlink:type=\"simple\">http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000900\/WC500034180.pdf<\/ext-link>. 2009 revised May 2016."},{"issue":"37","key":"ref19","doi-asserted-by":"crossref","first-page":"38379","DOI":"10.1074\/jbc.M404949200","article-title":"The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR)","volume":"279","author":"O Burk","year":"2004","journal-title":"J Biol Chem"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1146\/annurev.pharmtox.38.1.389","article-title":"In vitro and in vivo drug interactions involving human CYP3A","volume":"38","author":"KE Thummel","year":"1998","journal-title":"Annual review of pharmacology and toxicology"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2217\/pgs.12.187","article-title":"CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy","volume":"14","author":"L Elens","year":"2013","journal-title":"Pharmacogenomics"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"P Kuehl","year":"2001","journal-title":"Nature genetics"},{"issue":"9","key":"ref23","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00008571-200112000-00005","article-title":"The genetic determinants of the CYP3A5 polymorphism","volume":"11","author":"E Hustert","year":"2001","journal-title":"Pharmacogenetics"},{"issue":"10","key":"ref24","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/clinchem\/48.10.1668","article-title":"CYP3A5 variant allele frequencies in Dutch Caucasians","volume":"48","author":"RH van Schaik","year":"2002","journal-title":"Clin Chem"},{"key":"ref25","unstructured":"European Centre for Disease Prevention and Control, WHO Regional Office for Europe. HIV\/AIDS surveillance in Europe 2014. Stockholm: ECDC; 2015. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/hiv-aids-surveillance-in-Europe-2014.pdf\" xlink:type=\"simple\">http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/hiv-aids-surveillance-in-Europe-2014.pdf<\/ext-link>."},{"key":"ref26","unstructured":"Institut scientifique de Sant\u00e9 publique (WIV-ISP). \u00c9pid\u00e9miologie du SIDA et de l&apos;infection \u00e0 VIH en Belgique. Situation au 31d\u00e9cembre 2014. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/epidemio.wiv-isp.be\/ID\/reports\/Rapport_VIH-SIDA_2014.pdf\" xlink:type=\"simple\">https:\/\/epidemio.wiv-isp.be\/ID\/reports\/Rapport_VIH-SIDA_2014.pdf<\/ext-link>."},{"key":"ref27","unstructured":"Centers for Disease Control and Prevention (CDC): HIV Among African Americans. 2015. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.cdc.gov\/hiv\/group\/racialethnic\/africanamericans\/\" xlink:type=\"simple\">http:\/\/www.cdc.gov\/hiv\/group\/racialethnic\/africanamericans\/<\/ext-link>."},{"issue":"20\u201321","key":"ref28","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.jchromb.2009.04.046","article-title":"Validation and clinical application of a high performance liquid chromatography tandem mass spectrometry (LC-MS\/MS) method for the quantitative determination of 10 anti-retrovirals in human peripheral blood mononuclear cells","volume":"877","author":"L Elens","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"5","key":"ref29","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1128\/AAC.01046-10","article-title":"Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials","volume":"55","author":"TN Kakuda","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Sch\u00f6ller-Gy\u00fcre M, Woodfall B, De Marez T, De Smedt G, Peeters M, Vandermeulen K, et al. Pharmacokinetics of TMC125 with atazanavir and atazanavir\/ritonavir. 8th International Congress on Drug Therapy in HIV infection. 12\u201316 November 2006, Glasgow, UK:Poster P278.","DOI":"10.1177\/135965350701200511"},{"issue":"7\u20138","key":"ref31","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.clinbiochem.2015.12.011","article-title":"Quantification of darunavir and etravirine in human peripheral blood mononuclear cells using high performance liquid chromatography tandem mass spectrometry (LC-MS\/MS), clinical application in a cohort of 110 HIV-1 infected patients and evidence of a potential drug-drug interaction","volume":"49","author":"L Belkhir","year":"2016","journal-title":"Clinical biochemistry"},{"issue":"5","key":"ref32","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1177\/135965350701200511","article-title":"Pharmacokinetics of darunavir\/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers","volume":"12","author":"M Scholler-Gyure","year":"2007","journal-title":"Antivir Ther"},{"issue":"11","key":"ref33","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/QAD.0b013e3282170ab1","article-title":"Pharmacokinetics and antiretroviral response to darunavir\/ritonavir and etravirine combination in patients with high-level viral resistance","volume":"21","author":"M Boffito","year":"2007","journal-title":"Aids"},{"issue":"16","key":"ref34","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1097\/QAD.0b013e32833d89fa","article-title":"Pharmacokinetics of etravirine, raltegravir and darunavir\/ritonavir in treatment experienced patients","volume":"24","author":"A Barrail-Tran","year":"2010","journal-title":"Aids"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"186987","DOI":"10.1155\/2012\/186987","article-title":"Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial","volume":"2012","author":"T Kakuda","year":"2012","journal-title":"AIDS research and treatment"},{"issue":"4","key":"ref36","first-page":"275","article-title":"Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents","volume":"35","author":"A Hsu","year":"1998","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"ref37","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/sj.clpt.6100117","article-title":"CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir","volume":"81","author":"F Josephson","year":"2007","journal-title":"Clinical pharmacology and therapeutics"},{"issue":"2","key":"ref38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/FTD.0b013e318280d0ad","article-title":"Discordant associations between SLCO1B1 521T\u2014&gt;C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146","volume":"35","author":"X Zhang","year":"2013","journal-title":"Ther Drug Monit"},{"key":"ref39","unstructured":"Morlat P. Prise en charge m\u00e9dicale des personnes vivant avec le VIH. Recommandations du groupe d&apos;experts\u2014Rapport 2013. 480 p."},{"key":"ref40","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Accessed on 6\/2\/2016. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf\" xlink:type=\"simple\">http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf<\/ext-link>."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0165631","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T17:01:56Z","timestamp":1657558916000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0165631"}},"subtitle":[],"editor":[{"given":"Giuseppe Vittorio","family":"De Socio","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,10,27]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,10,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0165631","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,27]]}}}